P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY

Detalles Bibliográficos
Autores principales: Yacoub, A., Borate, U., Rampal, R., Ali, H., Wang, E., Gerds, A., Hobbs, G., Kremyanskaya, M., Winton, E., O’Connell, C., Goel, S., Oh, S., Schiller, G., Assad, A., Erickson-Viitanen, S., Zhou, F., Daver, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430537/
http://dx.doi.org/10.1097/01.HS9.0000847120.16268.0f

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430537/
http://dx.doi.org/10.1097/01.HS9.0000847120.16268.0f

Ejemplares similares